Send to

Choose Destination
See comment in PubMed Commons below
Biomatter. 2013 Jan-Mar;3(1). pii: e24490. doi: 10.4161/biom.24490. Epub 2013 Jan 1.

Enhancing retention and efficacy of cardiosphere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel.

Author information

  • 1Capricor Inc.; 8700 Beverly Boulevard; Los Angeles, CA USA.
  • 2Cedars-Sinai Heart Institute; Los Angeles, CA USA.


Cardiosphere-derived cells (CDCs) are under clinical development and are currently being tested in a clinical trial enrolling patients who have undergone a myocardial infarction. CDCs are presently administered via infusion into the infarct-related artery and have been shown in early clinical trials to be effective agents of myocardial regeneration. This review describes the administration of CDCs in a hyaluronan-gelatin hydrogel via myocardial injection and the subsequent improvements in therapeutic benefit seen in animal models. Development of a next generation therapy involving the combination of CDCs and hydrogel is discussed.


ALLSTAR trial; CADUCEUS trial; cardiosphere-derived cells; hyaluronan-gelatin hydrogel; myocardial infarction

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Write to the Help Desk